This article was originally published in The Gray Sheet
Executive SummaryFirm's branched DNA Quantiplex HIV-1 RNA 3.0 viral load test will be released this summer for research use. The device offers improved sensitivity over the current 2.0 version and quantifies "as little as 50 copies/mL and a broad dynamic range (50 to 500,000 copies/mL) that eliminates the need for reflex testing," Chiron says
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.